Increased early systemic inflammation in ICU-acquired weakness; A prospective observational cohort study

Critical Care Medicine

Volumn 45, Issue 6, 2017, Pages 972-979

  Witteveen, Esther ^a   Wieske, Luuk ^a   Van Der Poll, Tom ^a   Van Der Schaaf, Marike ^a   Van Schaik, Ivo N ^a   Schultz, Marcus J ^a   Verhamme, Camiel ^a   Horn, Janneke ^a   De Beer, Friso M ^b   Bos, Lieuwe D J ^b   Glas, Gerie J ^b   Van Hooijdonk, Roosmarijn T M ^b   Hoogendijk, Arie J ^b   Huson, Mischa A ^b   Schouten, Laura R A ^b   Scicluna, Brendon P ^b   Straat, Marleen ^b   Van Vught, Lonneke A ^b   Wiewel, Maryse A ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NONE

Author keywords

Critical illness neuromyopathy; Cytokines; Inflammation; Inflammatory markers; Intensive care unit acquired weakness

Indexed keywords

FRACTALKINE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; AUTACOID; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; NETHERLANDS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TERTIARY CARE CENTER; WEAKNESS; BLOOD; CRITICAL ILLNESS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MIDDLE AGED; MUSCLE WEAKNESS; PHYSIOLOGY; REGRESSION ANALYSIS; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

AGED; BIOMARKERS; CHEMOKINE CX3CL1; CRITICAL ILLNESS; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTENSIVE CARE UNITS; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCLE WEAKNESS; NETHERLANDS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RESPIRATION, ARTIFICIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TERTIARY CARE CENTERS; TIME FACTORS;

EID: 85016122993     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000002408     Document Type: Article

References (36)

1. Latronico N, Bolton CF: Critical illness polyneuropathy and myopathy: A major cause of muscle weakness and paralysis. Lancet Neurol 2011; 10:931-941
2. Stevens RD, Marshall SA, Cornblath DR, et al: A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med 2009; 37(10 Suppl):S299-S308
3. Stevens RD, Dowdy DW, Michaels RK, et al: Neuromuscular dysfunction acquired in critical illness: A systematic review. Intensive Care Med 2007; 33:1876-1891
4. Kress JP, Hall JB: ICU-acquired weakness and recovery from critical illness. N Engl J Med 2014; 370:1626-1635
5. Marshall JC: Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001; 29(7 Suppl):S99-106
6. Hack CE, Zeerleder S: The endothelium in sepsis: Source of and a target for inflammation. Crit Care Med 2001; 29(7 Suppl):S21-S27
7. Bolton CF: Neuromuscular manifestations of critical illness. Muscle Nerve 2005; 32:140-163
8. Witteveen E, Wieske L, Verhamme C, et al: Muscle and nerve inflammation in intensive care unit-acquired weakness: A systematic translational review. J Neurol Sci 2014; 345:15-25
9. Witteveen E, Schultz MJ, Horn J: The role of local and systemic inflammation in the pathogenesis of intensive care unit-acquired weakness. In: Annual Update in Intensive Care and Emergency Medicine 2015. Switzerland, Springer International Publishing, 2015, pp 509-518
10. van Swieten JC, Koudstaal PJ, Visser MC, et al: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19:604-607
11. Klein Klouwenberg PM, Ong DS, Bos LD, et al: Interobserver agreement of Centers for Disease Control and Prevention criteria for classifying infections in critically ill patients. Crit Care Med 2013; 41:2373-2378
12. Bone RC, Sibbald WJ, Sprung CL: The ACCP-SCCM consensus conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655
13. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39:165-228
14. Sainani KL: Introduction to principal components analysis. PM R 2014; 6:275-278
15. Helmy A, Antoniades CA, Guilfoyle MR, et al: Principal component analysis of the cytokine and chemokine response to human traumatic brain injury. PLoS One 2012; 7:e39677
16. Weber-Carstens S, Deja M, Koch S, et al: Risk factors in critical illness myopathy during the early course of critical illness: A prospective observational study. Crit Care 2010; 14:R119
17. Mohammadi B, Schedel I, Graf K, et al: Role of endotoxin in the pathogenesis of critical illness polyneuropathy. J Neurol 2008; 255:265-272
18. Fan E, Cheek F, Chlan L, et al; ATS Committee on ICU-acquired Weakness in Adults; American Thoracic Society: An official American Thoracic Society Clinical Practice guideline: The diagnosis of intensive care unit-acquired weakness in adults. Am J Respir Crit Care Med 2014; 190:1437-1446
19. Sharshar T, Citerio G, Andrews PJ, et al: Neurological examination of critically ill patients: A pragmatic approach. Report of an ESICM expert panel. Intensive Care Med 2014; 40:484-495
20. Winkelman C, Johnson KD, Gordon N: Associations between muscle-related cytokines and selected patient outcomes in the ICU. Biol Res Nurs 2015; 17:125-134
21. Verheul GA, de Jongh-Leuvenink J, Op de Coul AA, et al: Tumor necrosis factor and interleukin-6 in critical illness polyneuromyopathy. Clin Neurol Neurosurg 1994; 96:300-304
22. Aziz M, Jacob A, Yang WL, et al: Current trends in inflammatory and immunomodulatory mediators in sepsis. J Leukoc Biol 2013; 93:329-342
23. Imaizumi T, Yoshida H, Satoh K: Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 2004; 11:15-21
24. Hoogendijk AJ, Wiewel MA, van Vught LA, et al; MARS consortium: Plasma fractalkine is a sustained marker of disease severity and outcome in sepsis patients. Crit Care 2015; 19:412
25. Pierrakos C, Vincent JL: Sepsis biomarkers: A review. Crit Care 2010; 14:R15
26. Pachot A, Lepape A, Vey S, et al: Systemic transcriptional analysis in survivor and non-survivor septic shock patients: A preliminary study. Immunol Lett 2006; 106:63-71
27. Winkelman C: Inactivity and inflammation: Selected cytokines as biologic mediators in muscle dysfunction during critical illness. AACN Clin Issues 2004; 15:74-82
28. Brinkmeier H, Kaspar A, Wiethölter H, et al: Interleukin-2 inhibits sodium currents in human muscle cells. Pflugers Arch 1992; 420:621-623
29. Callahan LA, Supinski GS: Sepsis-induced myopathy. Crit Care Med 2009; 37(10 Suppl):S354-S367
30. Borge BA, Kalland KH, Olsen S, et al: Cytokines are produced locally by myocytes in rat skeletal muscle during endotoxemia. Am J Physiol Heart Circ Physiol 2009; 296:H735-H744
31. Langhans C, Weber-Carstens S, Schmidt F, et al: Inflammationinduced acute phase response in skeletal muscle and critical illness myopathy. PLoS One 2014; 9:e92048
32. Pedersen BK: Muscles and their myokines. J Exp Biol 2011; 214(Pt 2):337-346
33. Lightfoot A, McArdle A, Griffiths RD: Muscle in defense. Crit Care Med 2009; 37(10 Suppl):S384-S390
34. Zonneveld R, Martinelli R, Shapiro NI, et al: Soluble adhesion molecules as markers for sepsis and the potential pathophysiological discrepancy in neonates, children and adults. Crit Care 2014; 18:204
35. Seidelin JB, Nielsen OH, Strøm J: Soluble L-selectin levels predict survival in sepsis. Intensive Care Med 2002; 28:1613-1618
36. Latronico N, Bertolini G, Guarneri B, et al: Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: The Italian multi-centre CRIMYNE study. Crit Care 2007; 11:R11